Company Information
Company Profile
Cash Flow Statement
Profit & Loss
Financial Position
Financial Ratio
Industry 制造业
Company Introduction 浙江康恩贝制药股份有限公司是一家主要从事药品的生产、销售和研发销售业务的公司.公司的主导产品为前列康牌普乐安片与胶囊、天保宁牌银杏叶片、天保康牌葛根素注射液、康恩贝牌刻停片、乌灵胶囊.公司系国家中药五十强企业,为国家科技部认定的火炬计划重点高新技术企业.公司及子公司均已全面通过GMP认证或GSP认证.2010年,申请国家发明专利10项,获国家发明专利授权6项;申报省级以上科技项目21项,其中国家级5项,其中"银杏叶制剂生产过程质量控制先进技术产业化示范"项目获批国家发改委中药产业化专项,"银杏叶关键技术研究与国际认证"获批国家发改委、科技部"十二五"重大新药创新项目立项.新立项研发项目28项,总在研项目80余项,其中创新药物19项.中药六类新药黄莪胶囊通过技术审评,生产批件已在审批阶段.中药五类新药菊花舒心片启动Ⅱa期临床试验.完成化药三类新药瑞舒伐他汀钙原料及片剂临床试验.7个产品申报注册获受理.获得药品生产批件3项和保健食品生产批件1项。
Main Business 药品、中药饮片及大健康产品的研发、制造及销售。
Legal Representative 姜毅
Top Executives
董事长：姜毅
名誉董事长：胡季强
董事：吴律文,刘圣东,蒋倩,叶剑锋
独立董事：邱保印,牛宇龙,曾苏
Top 5 Shareholder
Shareholder name Nature Holding Date
浙江省医药健康产业集团有限公司流通A股23.12%30/09/2024
康恩贝集团有限公司流通A股9.90%30/09/2024
胡季强流通A股3.99%30/09/2024
浙江大华投资发展有限公司流通A股1.58%30/09/2024
香港中央结算有限公司流通A股1.34%30/09/2024
Company Secretary 金祖成
Solicitors 上海东方华银律师事务所
Auditors 天健会计师事务所（特殊普通合伙）
Tel No 0571-87774828
Fax No 0571-87774722
Website www.conba.com.cn
Email conbazq@conbapharm.com
Company Address
Register: 浙江省金华市兰溪市康恩贝大道1号
Office: 浙江省杭州市高新技术开发区滨江科技经济园滨康路568号
Listing Date 12/04/2004
Shares Capital
Shares Capital: 2,570,037,319
Total A Share: 2,570,037,319
Listed A Share: 2,563,295,466
Non-tradable A Share: 6,741,853
Other Share: 0
Total B Share: 0
Total H Share: 0
EPS(RMB)* ¥ 0.230
DPS(RMB)* ¥ 0.200
NBV Per Share(RMB)* ¥ 2.740
Market Capitalization(RMB) 12.253B
Smiley face Only Chinese content is avaliable
N
/
N
 : Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SH-HK Ex-Northbound trade (sell only)
N
/
N
 : Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
* Unadjusted Data
Information provided by: etnet
Terms and Conditions
Risk Disclosure:
The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone.
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.